Evidence map›Paper›PMID 42162438›Full record

ReviewDocumenta ophthalmologica. Advances in ophthalmology2026

Clinical endpoints special session, ISCEV 2025, Utrecht.

R Hamilton, D Birch, K Stingl, K Fujinami, K Holopigian, C J F Boon, J Moseley, J J McAnany, A V Cideciyan, M M van Genderen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Documenta ophthalmologica. Advances in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

R HamiltonDepartment of Clinical Physics & Bioengineering, Royal Hospital for Children, Glasgow, UK.ORCID http://orcid.org/0000-0002-0855-9533
D BirchRetina Foundation of the Southwest, Dallas, USA.ORCID http://orcid.org/0000-0002-6594-2897
K StinglUniversity Eye Hospital, Center for Ophthalmology, University of Tübingen, Elfriede-Aulhorn-Straße 7, 72076, Tübingen, Germany. Katarina.Stingl@med.uni-tuebingen.de.ORCID http://orcid.org/0000-0002-8132-911X
K FujinamiLaboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4248-0033
K HolopigianNovartis Pharmaceuticals Corporation, East Hanover, USA.ORCID http://orcid.org/0000-0001-8725-4051
C J F BoonAmsterdam University Medical Center, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-4625-6795
J MoseleyEuropean Medicines Agency, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-4889-5953
J J McAnanyDepartment of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, USA.ORCID http://orcid.org/0000-0003-1192-3487
A V CideciyanCenter for Hereditary Retinal Degenerations, Scheie Eye Institute, University of Pennsylvania, Philadelphia, USA.ORCID http://orcid.org/0000-0002-2018-0905
M M van GenderenBartiméus Diagnostic Center for Complex Visual Disorders, Zeist, The Netherlands.ORCID http://orcid.org/0000-0002-9286-8397

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report summarises the Clinical Endpoints Special Session held during the 62nd annual symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV), convened at Tivoli Vredenburg, Utrecht, The Netherlands. The session brought together clinicians, regulators, industry representatives, and a patient voice to consider the state of clinical endpoints in trials for inherited retinal disorders (IRDs). Discussions covered the adequacy of current endpoints, challenges of disease heterogeneity, regulatory expectations, operational feasibility, and the perspectives of patients. The session highlighted the need to anchor emerging endpoints to clinically meaningful outcomes and to minimise assessment burdens.

Indexed as

Clinical Trials as TopicEndpoint DeterminationRetinal DiseasesSocieties, MedicalHumansClinical endpointsClinical trialsPatients perspectiveRetinal dystrophies

Identifiers

PMID42162438
PMCPMC13506647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.